Skip to content
Breo ellipta, Relvar ellipta(vilanterol acetate)
Anoro, Anoro Ellipta, Ellipta, Laventair, Laventair Ellipta (vilanterol acetate) is a small molecule pharmaceutical. Vilanterol acetate was first approved as Breo ellipta on 2013-05-10. It has been approved in Europe to treat asthma and chronic obstructive pulmonary disease.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Combinations
Anoro ellipta, Breo ellipta, Trelegy ellipta
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fluticasone furoate
+
Umeclidinium bromide
+
Vilanterol trifenatate
Tradename
Company
Number
Date
Products
TRELEGY ELLIPTAGSKN-209482 RX2017-09-18
2 products, RLD, RS
Fluticasone furoate
+
Vilanterol trifenatate
Tradename
Company
Number
Date
Products
BREO ELLIPTAGSKN-204275 RX2013-05-10
3 products, RLD, RS
Umeclidinium bromide
+
Vilanterol trifenatate
Tradename
Company
Number
Date
Products
ANORO ELLIPTAGSKN-203975 RX2013-12-18
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
anoro elliptaNew Drug Application2020-08-06
breo elliptaNew Drug Application2021-07-26
trelegy elliptaNew Drug Application2020-09-09
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
FLUTICASONE FUROATE / VILANTEROL TRIFENATATE, BREO ELLIPTA, GLAXO GRP LTD
2026-05-13NPP, NS
FLUTICASONE FUROATE / UMECLIDINIUM BROMIDE / VILANTEROL TRIFENATATE, TRELEGY ELLIPTA, GLAXOSMITHKLINE
2023-09-09I-843, NS
Patent Expiration
Patent
Expires
Flag
FDA Information
Fluticasone Furoate / Umeclidinium Bromide / Vilanterol Trifenatate, Trelegy Ellipta, Glaxosmithkline
97507262030-11-29DP
110902942030-11-29U-3202, U-3203
87462422030-10-11DP
85342812030-03-08DP
81619682028-02-05DP
74888272027-12-18DS, DP
81131992027-10-23DP
93333102027-10-02DP
85113042027-06-14DPU-1424, U-1476, U-1691, U-2954
81832572025-07-27U-1476, U-2128, U-2129
74393932025-05-21DS, DPU-1401, U-1476, U-1691, U-2099, U-2100, U-2127, U-2957
74984402025-04-27DS, DP
83095722025-04-27U-1476, U-2129
RE448742023-03-23DS, DPU-1476, U-1548, U-1691, U-2127, U-2955
Fluticasone Furoate / Vilanterol Trifenatate, Breo Ellipta, Glaxo Grp Ltd
111167212029-02-26DPU-1401, U-1691
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AK: Adrenergics inhalants in combination with corticosteroids or other drugs, excl. anticholinergics
— R03AK10: Vilanterol and fluticasone furoate
— R03AL: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
— R03AL03: Vilanterol and umeclidinium bromide
— R03AL08: Vilanterol, umeclidinium bromide and fluticasone furoate
HCPCS
No data
Clinical
Clinical Trials
72 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.954229645
AsthmaD001249EFO_0000270J4557134—27
Heart failureD006333EFO_0003144I50———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD010599—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVILANTEROL ACETATE
INNvilanterol
Description
Anoro, Anoro Ellipta, Ellipta, Laventair, Laventair Ellipta (vilanterol acetate) is a small molecule pharmaceutical. Vilanterol acetate was first approved as Breo ellipta on 2013-05-10. It has been approved in Europe to treat asthma and chronic obstructive pulmonary disease.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)O.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1084647
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID028LZY775B (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Trelegy ellipta - Innoviva, Inc.
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,686 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,884 adverse events reported
View more details